Jump to main content
Jump to site search

Issue 12, 2013
Previous Article Next Article

Dual mode of action of phenyl-pyrazole-phenyl (6-5-6 system)-based PPI inhibitors: alpha-helix backbone versus alpha-helix binding epitope

Author affiliations

Abstract

A new class of alpha-helix mimetics, based on the phenyl-pyrazole-phenyl (6-5-6) system, has been designed and synthesized. The ability of the new compounds to inhibit PPIs was confirmed using an MDM2-p53 binding assay. The library, containing completely new compounds, revealed an excellent hit rate of 15%, had satisfactory physicochemical properties (~38% soluble compounds), and the ligand efficiency of the best compound was 0.21 (0.22 for nutlin-3 in the same assay). Dual mode of action of these inhibitors was suggested based on computer modeling: depending on the nature of their substituents they could act as either an alpha-helix backbone mimetic or an alpha-helix binding epitope mimetic.

Graphical abstract: Dual mode of action of phenyl-pyrazole-phenyl (6-5-6 system)-based PPI inhibitors: alpha-helix backbone versus alpha-helix binding epitope

Back to tab navigation

Supplementary files

Publication details

The article was received on 24 Jul 2013, accepted on 20 Sep 2013 and first published on 20 Sep 2013


Article type: Concise Article
DOI: 10.1039/C3MD00211J
Med. Chem. Commun., 2013,4, 1597-1603

  •   Request permissions

    Dual mode of action of phenyl-pyrazole-phenyl (6-5-6 system)-based PPI inhibitors: alpha-helix backbone versus alpha-helix binding epitope

    N. I. Vasilevich, I. I. Afanasyev, E. A. Rastorguev, D. V. Genis and V. S. Kochubey, Med. Chem. Commun., 2013, 4, 1597
    DOI: 10.1039/C3MD00211J

Search articles by author

Spotlight

Advertisements